Sharp Services announced a significant expansion of its Macungie, Pennsylvania site, doubling its size to 315,000 square feet and enhancing production capacity for sterile injectable secondary packaging, including vial labeling, pre-filled syringe assembly, and autoinjector packaging. The expansion - driven by increasing demand for biologics and injectable medicines - will also add new packaging suites, cold storage, and create 75-100 new jobs.

Despite its parent company facing scrutiny and potential sanctions from the U.S. government, WuXi AppTec continues to expand its contract research, development and manufacturing organization (CRDMO) services in its native China.

Japan headquartered chemicals group, Asahi Kasei, is expanding its Bionova CDMO’s services to include plasmid DNA (pDNA) production for cell and gene therapy developers by establishing a new facility in The Woodlands, Texas, where it is set to begin research-grade pDNA production in early 2025 and GMP manufacturing later that year.

The FDA has introduced guidance for platform technology designations that is designed to streamline regulatory processes for biotech companies using ‘well-understood and reproducible technology’, such as specific nucleic acid sequences, vectors or delivery methods, to expedite subsequent drug applications.

Ask any executive why they think there are drug shortages, and they will no doubt blame some combination of the long-lasting impact of the global pandemic, inflation, energy costs and global conflicts.

The San Francisco-based biotech secured $225 million to further develop its immune checkpoint enhancer, ALTB-268. This novel therapy aims to treat autoimmune and inflammatory diseases by regulating overactive immune responses without affecting normal immune defenses.

A significant rise in biotech stocks has been partly attributed to escalating fears over avian influenza and the ongoing development of related vaccines.

Merck KGaA announced a definitive agreement to acquire Mirus Bio, strengthening its biopharmaceutical manufacturing and gene therapy capabilities.

To meet increased market demand for parenteral manufacturing, leading CDMO Alcami has announced the strategic expansion of its sterile fill-finish manufacturing capabilities and capacity for a total of six fill-finish lines.

The Indianapolis-based drugmaker has announced it will increase its investment at its newest, 600-acre Lebanon, Indiana, site by $5.3 Bn, where it will make tirzepatide, the API used for its type-2 diabetes drug Mounjaro and obesity treatment Zepbound.

Sanofi has announced a collaboration with OpenAI, the ChatGPT parent, and Formation Bio, a technology-driven drug developer with a pipeline of drug assets, to accelerate drug development.

In response to President Biden’s Executive Order 14081, the EPA, FDA, and USDA have jointly unveiled a plan to streamline the regulation of biotech innovations in plants, animals, and microorganisms.

AstraZeneca has set an ambitious goal to achieve $80 bn in revenue by 2030, following on from their successful strategy that managed to generate $45 bn in revenue in 2023.

The Biotechnology Innovation Organization (BIO) has announced a significant restructuring initiative, which includes laying off staff to streamline operations to enhance the group's lobbying effectiveness at better supporting the biotechnology industry.

Tourmaline Bio has dosed the first patient in its Phase 2 TRANQUILITY trial for TOUR006, an anti-IL-6 monoclonal antibody aimed at treating atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular conditions.

GRI Bio, Inc. has announced positive preclinical data for its lead program, GRI-0621, in treating Idiopathic Pulmonary Fibrosis (IPF).

For the remainder of this decade, the biologics industry could experience significant growth driven by the incidence of chronic diseases and the rise of autoimmune disorders due to aging populations and lifestyle changes – likely to fuel the demand for biologics as treatment options.

The move comes amidst increasing geopolitical tensions and a U.S. biosecurity crackdown, in which it was alleged that the company transferred the data of a US client to Beijing ‘without consent’.

Novo’s proposed acquisition of Catalent, with the immediate goal of adding capacity for its weight-loss drugs, has rarely been out of the news, whilst a raft of expansions elsewhere has been announced at Thermo Fisher, Alcami, Lonza and Vetter, to list but a few.

Jan van de Winkel, CEO of one of Europe’s leading biotech companies, Genmab, highlighted the need for Western pharma companies to embrace Chinese biotech innovation, despite growing anti-Chinese sentiment in the US.